Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis
1 Department of Rheumatology and Clinical Immunology, Free University and Humboldt University Berlin, Charité University Medicine Berlin, Charitéplatz 1, 10117, Berlin, Germany. gerd.burmester@charite.de.
2 Veszprém Csolnoky Ferenc County Hospital, Veszprém, Hungary.
3 Rheumatology, Koscian Municipal Hospital, Koscian, Poland.
4 Amgen Inc., Thousand Oaks, CA, USA.
5 Metroplex Clinical Research Center, Dallas, TX, USA.